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UNIT COSTS OF INPATIENT DEPARTMENT SPECIAL WARD OF BANPHAEO
HOSPITAL (PUBLIC ORGANIZATION)
Maitreemit P1, Tongchun S2
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nakornpathom pro, Thailand
OBJECTIVES: To examine the unit cost of inpatient service department of special
ward at Banphaeo Hospital that reformed to be Public Organization( the new
model) in Thailand. METHODS: Cost analysis from provider’s perspective. Cost
center was divided by function and the support units in hospitals into three cate-
gories: (1)Patient service PS (2) Revenue producing cost center RPCC ; and (3) non
revenue producing cost center NRPCC. Total direct costs were composed of labour
costs, material costs and capital costs. Indirect costs were allocated by using direct
distribution method. RESULTS: The total cost of private ward 4/2 was
17,278,303.45 . The total cost in private ward 4/2 consisted of labour cost was
3,739,743.60 , material cost was 1,242,991.36 Capital cost was 2,733,735.87 . The
ratio of lobour cost: material cost: capital cost was 48.46: 16.11: 35.43 and ratio of
indirect cost was 55.34. The unit cost of inpatient department private ward 4/2 was
16,239 per case ; routine service cost was 9,226 . 10 and medical care cost was
7,012.90 CONCLUSIONS: The results were useful in decision making for resource
allocation. It can be used to facilitate comparison of different studies in various
type of organization of hospital administration.
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PNEUMOCOCCAL VACCINES COST-EFFECTIVENESS ANALYSES
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OBJECTIVES: o review the approach used in the CEA literature to estimate the cost
of EPI activities, other than vaccine purchase, for rotavirus and pneumococcal
vaccines. METHODS: A systematic review in PubMed database of rotavirus and
pneumococcal vaccines CEAs was done. Selected articles were read and informa-
tion on how EPI costs were calculated was extracted. EPI costing approaches were
classified according to the method or assumption used for estimation. RESULTS:
Thirty studies that evaluated Cost effectiveness of rota (n19) or pneumococcal
(n11) vaccines were identified. In general there are very few details on how EPI
costs different to vaccine purchasing were estimated. Only 2 studies (Canada) on
pneumococcal vaccine used a primary cost evaluations (micro costing) while 8
studies did not consider any additional EPI cost beyond vaccine purchasing. Eigh-
teen studies considered an overall administrative costs ranging betweenUS$0.5-10
per dose, but most of them did not provide any clue on the basis of that assump-
tion. Only 2 studies considered clearly costs related to personnel time or activities
which is a critical component of EPI costs.CONCLUSIONS:Most pneumococcal and
rotavirus cost-effectiveness analysis reviewednot considered additional EPI cost or
use assumptions based in no or few evidence. Ignoring additional EPI costs to
vaccine purchasing in CEA analysis of new vaccines may lead to significant errors
in the estimations of ICER since several aspects like cold chain, promotion activi-
ties or personnel can be substantially affected for the introduction of new vaccines.
This may lead to mistakes in the decision making process.
RESEARCH ON METHODS – Databases & Management Methods
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OBJECTIVES: There is growing interest in using patient-reported outcome (PRO)
measures, which can complement clinical measures, to improve the quality of
health care. The amount of PRO data being captured by health care databases,
however, is unknown. To help identify data sources that capture PRO measures
and the types of PRO data they collect, a systematic review was conducted in
B.R.I.D.G.E. TO DATA® (www.bridgetodata.org), an online resource of population
healthcare database profiles worldwide. METHODS: PRO data were categorized
into 9 dimensions of health status (Fitzpatrick et al., 1998): physical function, symp-
toms, self-judgments of health, psychological well-being, social well-being, cogni-
tive function, role activities, personal constructs, and satisfaction with care. To
identify data sources collecting PRO data, 154 database profiles in www.bridgeto-
data.org were individually reviewed. The PRO category and specific data subcate-
gory (e.g., symptoms-appetite) were also extracted. RESULTS: A review of 154 da-
tabase profiles resulted in the identification of 34 databases that collect data on:
physical function (22), symptoms (19), psychological well-being (15), social well-
being (11), cognitive function (9), role activities (6), personal constructs (4), satisfac-
tion with care (2), and self-judgments of health (1). Three additional databases
(from UK, Netherlands, and Canada) collect PRO-related data upon request. The
majority of databases found to report PRO data are longitudinal and/or cross-sec-
tional, particularly survey data in populations of 200,000. US, Canadian, and UK
databases commonly report PRO data. Database characteristics vary among PRO
categories, including cognitive function, where population type primarily com-
prises of people from specialty institutions. CONCLUSIONS: Within 154 database
profiles that were reviewed, symptoms and physical function are the most fre-
quently collected PRO data types, while patient satisfaction with care and self-
judgments of health are least likely to be found. Reporting PRO data has become
increasingly important for health care; however, this study shows that less than
25% of databases collect any PRO data.
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OBJECTIVES: Secondary data sources can provide a wide variety of useful data for
research studies, but their utility depends on their validity. It is unclear whether
the extent to which secondary sources are used differs between research-oriented
and practice-oriented journals. The objectives of this study were to describe the
proportion of original research articles using secondary data, the types of second-
ary data being used, andwhether validationwasmentionedwhile comparing these
findings between two types of journals. METHODS: All original research articles
published in 2010 from selected practice-oriented journals (New England Journal of
Medicine, Archives of Internal Medicine, Pharmacotherapy, Annals of Pharmacotherapy)
and research-oriented journals (Value in Health, Medical Care, Health Services Re-
search) were reviewed. The complete text of each article was examined to deter-
mine whether secondary data were used, the type of secondary data used, and
whether validation of the data wasmentioned. The proportion of original research
articles using secondary data and the mention of validation was compared be-
tween the two types of journals using Fisher’s exact test. RESULTS: There were 192
and 425 original research articles for the research- and practice-oriented articles,
respectively. Overall, 44.1% of research articles used secondary data. Articles in
research-oriented journals were more likely than practice-oriented journals to use
secondary data (69.8% vs. 32.5%, respectively; p 0.001) and to mention validation
(17.2% versus 5.8%, respectively; p  0.003). Administrative data were the most
common secondary data source in the research journals compared to medical
records in the practice journals. CONCLUSIONS: The use of secondary sources was
more common in research-oriented journals than in practice-oriented journals. A
variety of secondary sources were used in published articles. Validation was men-
tionedmore frequently in research journals than in practice journals, but the over-
all percentage was relatively low for both types of journals.
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OBJECTIVES: Health economic researchers use electronic databases to review cur-
rent and ancestral literature across therapy areas. In the United States and Canada,
researchers tend to use MEDLINE, and in other parts of the world EMBASE is the
literature database of choice. EMBASE is fee-based and MEDLINE is available gratis
through the National Library of Medicine. Using the search engine OVID, both
databases can be searched simultaneously, with a paid subscription. MEDLINE
indexes 5600 journals and EMBASE indexes 7600 journals; all MEDLINE records are
included in EMBASE. EMBASE also includes conference abstracts which MEDLINE
does not. Additionally, EMBASE assigns more index terms to references thanMED-
LINE which can result in less focused searches. The researchers were interested in
comparing and contrasting search results in both databases, particularly in the
area of health economics. METHODS: Researchers selected three broad search
terms: cost of illness (COI), burden of illness (BOI) and cost benefit analysis (CBA)
that would be recognized in both databases. Each search was run with chronic
pulmonary obstructive disease as the treatment focus, 2010-2011, English only.
RESULTS: The results were unexpectedly mixed. In the area of CBA, MEDLINE
generated a higher number of references, 30 versus 17 in EMBASE with 11 dupli-
cated records. COI and BOI searches resulted in a larger number of citations for
EMBASE, 11 and 149, versus 7 and 105 for MEDLINE with 6 and 101 duplicates,
respectively. Conference abstracts accounted for the higher number of hits in EM-
BASE over MEDLINE. CONCLUSIONS: Health economic researchers rely on the
most up-to-date information to identify cost and treatment trends and the inclu-
sion of conference abstracts in EMBASE support conducting these searches using
both databases, particularly for systematic literature reviewswhere use of EMBASE
could be a requirement. Further examination into the nuances of search terms and
indexing in both databases is warranted.
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COMPARISON OF METHODS FOR THE EVALUATION OF USTEKINUMAB DOSING
AND COSTS IN PHARMACY CLAIMS DATABASES
Carter C1, Haas S2, Gunnarsson C2, Martin S3
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2S2 Statistical Solutions, Inc., Cincinnati, OH,
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OBJECTIVES: To describe and compare two methods of ustekinumab drug utiliza-
tion evaluation in pharmacy claims. METHODS: Method I (fill pattern) was a drug
utilization assessment based on unadjusted raw claims. The National Drug Code,
quantity, days supplied, and cost of prescription were used. Method II (dosing
pattern) enhanced Method I by combining information on the current claim with
information on time to next prescription. This enhancement accounted for multi-
ple vials/syringes dispensed in a single claim to cover two doses. Only patientswith
2 ustekinumab prescriptions and meeting dosing algorithm requirements were
eligible forMethod II. A comparison of dosing results fromWolters Kluwer Source®
Lx, across the first three ustekinumab prescriptions, was used for illustration. Cal-
culated ustekinumab cost per injection was based on Wholesale Acquisition Cost
(effective 7/5/2011) of $5,485.22 per 45mg and distribution of 45 mg and 90 mg
dosing events. RESULTS: Data from 1039 patients were evaluated in Method I. A
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subgroup of patients (N473) eligible for evaluation under Method II was also eval-
uated under Method I, to assess differences in results compared with the overall
population. Method I yielded higher dose estimates when compared to Method II.
This was consistent for the total sample and subgroup. Ustekinumab cost per
injection in Method I was estimated up to 68.2% higher than in Method II. Variabil-
ity in cost estimates across doses was up to 18 times higher in Method I than
Method II. CONCLUSIONS: Conducting ustekinumab drug utilization assessments
with pharmacy claims requires a methodological adjustment to address multiple
doses dispensed on the same claim. Unadjusted assessment may yield artificially
high dose and cost estimates. Adjusted assessments offer a more realistic distri-
bution of dose and less variability in cost estimates. The ability to conduct adjusted
assessments requires the sample to have  2 ustekinumab prescriptions and suf-
ficient follow-up time.
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PROQOLID DATABASE: WHERE ARE WE TEN YEARS AFTER ITS LAUNCH?
Emery MP, Caron M, Perrier LL
MAPI Research Trust, Lyon, France
OBJECTIVES: The PROQOLID database was developed in mid-2001 to provide all
those involved in health care evaluation with a comprehensive and unique source
of information on Patient-Reported Outcomes (PRO) and Health-Related Quality of
Life (HRQL) measures available through the Internet. The objective of this study is
to review the evolution of content, structure, and functionality of the PROQOLID
database over this ten-year period (2002-2011). METHODS: The archives of PRO-
QOLIDwere searched to retrieve the database just before its launch and to compare
its content and structure as it is in December 2011. RESULTS: The September 2001
database (then known as QOLID) was retrieved. It included 313 instruments (32
generic and 281 disease- or condition-specific). Instruments specific to oncology
were themost frequent (54). The structurewas simplewith only three categories in
the membership level: contact, conditions of use, and a copy of the questionnaire.
By comparison, the December 2011 database includes 711 instruments (an increase
of 127%, with 99 generic and 612 disease- or condition-specific), with an increase of
almost 40 instruments each year (up by 398 in ten years). Instruments specific to
nervous system diseases are now the most frequent (139). The information dis-
played for each instrument has considerably been improved with the addition of
five categories in the membership level: translations available, descriptive infor-
mation, content validity documentation, measurement properties, references and
websites. A search engine has been added to enable advanced searches with the
following criteria: abbreviation, full name, author, dimension, disease, type of in-
strument, population, and languages. In January 2005 the database was renamed
PROQOLID to reflect the wider use of the term Patient-Reported Outcomes.
CONCLUSIONS: In a period of 10 years, the PROQOLID database has considerably
evolved in content, and structure, and offers a range of information and services
adapted to the evolution of the field.
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OBJECTIVES: Post-marketing surveillance for adverse effects has become an essen-
tial element of new drug andmedical devices development in the European Union
and the USA. The objective of this study is to present an overview of the content of
a database gathering the details of Regulatory Post-Marketing Studies (RPMS) re-
quested by the European Medicines Agency (EMA, EU), the Food and Drug Admin-
istration (FDA, USA) and the Haute Autorité de Santé (HAS, France).METHODS: All
drug approvals published by the EMA, the FDA and the HAS between January 1,
2005 and November 10, 2011 were reviewed to retrieve RPMS. The information was
categorized as follows: product description (brand name, INN, indication, etc.),
application details, RPMS details, and information source. RESULTS: For the FDA,
we reviewed 676 original approvals and 929 supplements and included, respec-
tively, 199 and 110 drugs approved with RPMS. For the EMA, we reviewed 333
marketing authorizations and included 33 files with RPMS. For the HAS, 3549 opin-
ions were published in this interval with only 174 opinions with RPMS. Many re-
quests of the HAS were long-term follow-up studies. About 43% of the RPMS re-
quested by the FDA were paediatric studies. Actually, the EMA also requires
paediatric studies but under a Paediatric Investigation Plan (PIP). Since 2005, 21 PIPs
have been requested. Whatever the agency, all kinds of indications are covered by
the RPMS, e.g., treatment of sepsis, asthma, malaria, depressive disorder, etc.
CONCLUSIONS: This project will be a unique source of centralized information
about RPMS requested in Europe and in the United States. It will be useful to
observe the current trends in studies requested, to anticipate the demands, and to
integrate the studies as early as possible in the product development process. The
database will be available online in an independent website, with access by sub-
scription.
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ACCESS TO REAL-WORLD DATABASES IN EUROPE – HOW TO FIND THE ONE
THAT WILL ANSWER YOUR RESEARCH QUESTION?
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OBJECTIVES: Increasingly regulators and payers world-wide are seeking real world
data (RWD) to inform decisions on access to new medicines. While the ISPOR
International Digest of Databases is a valuable resource to facilitate the access of
health outcome researchers to RWD, a limitation is that it depends on database
providers to submit database information to ISPOR. In this researchwe aim to build
on this initiative by searching specifically in the therapeutic areas of oncology,
cardiology and endocrinology for databases that can assist researchers to identify
suitable databases in Europe and test whether they can answer relevant research
questions. METHODS: The search was limited to the United Kingdom, Germany,
France and the Netherlands using generalized research questions. Review of the
existing initiatives supplemented with interviews was conducted to set the final
framework of the research and refine the attributes relevant to the therapeutic
areas. Secondary research was conducted to identify real world databases not
captured previously. The database holders were contacted by phone and/or email
to obtain further information on the specifics of the databases. RESULTS: Five
previous initiatives including ISPOR were identified and reviewed. A total of 122
databases were identified and assessed. Of these, 86 databases (70%) were not
mentioned in any of the previous initiatives. Oncology databases formed the ma-
jority of the databases (57), followed by endocrinology (14) and cardiology (13with
the other 38 databases covered multiple therapeutic areas. Information was gath-
ered on general details, disease specific outcome measures, as well as technical
details. CONCLUSIONS: Our non-exhaustive research has shown that databases
with the potential to answer these hypothetical research questions do exist in all
countries. This research helps identify potential sources for RWD analysis, but in
practice a well-defined research question is needed to assess the true suitability of
the database.
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A METHOD OF PROJECTING FUTURE CO-MORBIDITY PREVALENCE AND HEALTH
SERVICE DEMAND IN THE UNITED KINGDOM POPULATION USING THE HEALTH
IMPROVEMENT NETWORK (THIN)
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OBJECTIVES: It would be valuable for health care planning to project future popu-
lation co-morbidity conditions by studying the historical progression of patients
through the various possible health states, based on their initial health. This study
investigated a methodology of observing co-morbidity prevalence in the UK
population.METHODS: By using pre-collected data from The Health Improvement
Network (THIN) database of UK primary care records, the proportion of patients
who have one or more co-morbidities including hypertension, diabetes, heart dis-
ease, COPD and stroke can be observed for any given time period. A THIN data
extract was used to determine the transition rates between co-morbidity states, as
well as the mortality rates for each co-morbidity group. This was carried out by
‘measuring the central exposed to risk’, an actuarial analysis method, in each
group and using ‘forces of transition’ between the states. The number of doctor
visits which patients make per year, broken down by co-morbidity grouping, was
used as a potential proxy for historic demand for health services. RESULTS: Com-
bining data on the future population by age and sex, and the split between co-
morbidity groupings, we can estimate the total likely health service demand in the
future. CONCLUSIONS: This framework can be used to consider future scenarios,
seeking to address specific clinical issues or design policies that influence health
behaviour issues based on assumed changes in transition rates. For example, if
there were to be a one-year delay on the average age of diabetes onset, the impact
on the population’s health as well as the demand and cost of health provisions can
be estimated. Other examples of health scenarios that can bemodelled include the
effects of giving up smoking and reducing levels of obesity on co-morbidity and
thus the impact that lifestyle changes can have on future health service demand.
RESEARCH ON METHODS – Modeling Methods
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PHYSICIANS AS PSEUDO-AGENTS IN A HOSPITAL EMERGENCY DEPARTMENT
DISCRETE EVENT SIMULATION
Lim ME, Worster A, Goeree R, Tarride JE
McMaster University, Hamilton, ON, Canada
OBJECTIVES: Computer simulation studies of the emergency department (ED) of-
ten allow the patient to drive the process and do not consider indirect patient
related activities by the attending physician and resident (i.e. charting, teaching).
The objective of this study is to describe and evaluate an approach where physi-
cians are considered ‘pseudo-agents’ in a discrete event simulation (DES).
METHODS: Using data from an Ontario hospital, two ED DES models (traditional
versus pseudo-agent) were constructed and compared on key outputs including
time intervals and utilization rates. The traditional approachmodels the attending
physician and residents as human resources where their only function is to treat
patients. Additionally, residents are modeled similarly to the attending. The pseu-
do-agent approach allows for interaction between the attending physician and
residents, the use of different skill sets (attending treats more severe patients) and
decision-making hierarchy (physician prioritizes on treating a patient or teaching a
resident). These conceptswere implementedusing the simulation softwareARENA
13. RESULTS: Utilization of nursing staff and clerks remained similar. Physician
utilization rates increased by 50% in the pseudo-agent based model. There was no
change in the time from when the patient was placed in a room until the first
physician visit. Time until discharge or admission increased for patients with a
lower acuity in the pseudo-agent based model. As a result, time to room for these
patients also increased in addition to bed utilization. CONCLUSIONS: Computer
simulation models are more frequently being used to help inform hospital opera-
tional decision making. This example shows the importance of accurately model-
ing physician relationships and the rules in which they treat patients. Neglecting
these relationships could lead to inefficient resource allocation due to inaccurate
estimates of resource utilization and waiting times.
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